Back to search
FDAFDA · Food and drugs·Recall number D-0311-2020

Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured by: Novitium Pharma LLC 70 Lake Drive, East Windsor, New Jersey 08520 NDC 70954-001-40

Published November 20, 2019 · Recall initiated: October 25, 2019

Summary

FDA records drug Class II recall D-0311-2020, published November 20, 2019 and initiated October 25, 2019. Recalling firm: Novitium Pharma LLC; Status: Terminated; Reported quantity: 2718 bottles; Lot: all lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Novitium Pharma LLC
Distributor
Nationwide
Lot
all lots within expiry.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured by: Novitium Pharma LLC 70 Lake Drive, East Windsor, New Jersey 08520 NDC 70954-001-40 recalled?

Yes. FDA published recall D-0311-2020 on November 20, 2019. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter